ÂÜÀòÂÒÂ×

Dr. Lobo joined Inhibrx in 2020 and is responsible for the formulation development and drug product manufacturing of early and late-stage molecules in the Inhibrx pipeline. He brings over 20 years of biopharmaceutical industry experience in the biophysical characterization, drug delivery, formulation development, and parenteral manufacturing of small molecule and biologic drugs, including antibody and fusion proteins, peptides, antibody-drug conjugates, and mRNA-based lipid nanoparticle modalities.

Prior to joining Inhibrx, Dr. Lobo led development teams and developed drug products at Merck, Genentech, Amylin Pharmaceuticals, MedImmune/AstraZeneca, and Ultragenyx Pharmaceutical.

Dr. Lobo received his B.S. in Pharmacy from Rutgers University and his Ph.D. in Pharmaceutical Chemistry from the University of Kansas.